Physician profile
James Maturo
NPI 1245239813
$7,003.04
in general payments reported to CMS, 2019-2025
46 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $640 · 2021: $637 · 2022: $1,121 · 2023: $971 · 2024: $1,261 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,128.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $972.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $550.30 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $534.29 | 2019-2025 | |
| Abbott Laboratories | $518.06 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $459.74 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $432.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $274.11 | 2019-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.91 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Kerecis Limited | $196.17 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Amarin Pharma, INC. | $189.75 | 2019-2021 | |
| Glaxosmithkline, LLC. | $168.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Integra Lifesciences Corporation | $120.92 | 2019 | |
| Mimedx Group, INC. | $107.42 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.30 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $78.41 | 2025 | Gemtesa, Myfembree |
| Exact Sciences Corporation | $77.97 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $65.79 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $64.20 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Phathom Pharmaceuticals, INC. | $59.51 | 2024-2025 | Voquezna |
| Corium, LLC | $43.86 | 2022 | |
| Medtronic, INC. | $42.85 | 2022 | |
| Esperion Therapeutics, INC. | $42.74 | 2025 | Nexletol |
| Axsome Therapeutics, INC. | $42.47 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $38.34 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.17 | 2022 | |
| Organogenesis INC. | $36.94 | 2024-2025 | Puraply Wound Matrix |
| Allergan, INC. | $36.23 | 2019-2020 | |
| Dexcom, INC. | $34.55 | 2024-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $32.85 | 2023 | Omnipod |
| Boston Scientific Corporation | $32.67 | 2019-2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $30.28 | 2022-2023 | |
| Polynovo North America LLC | $24.70 | 2025 | Novosorb Btm |
| Smith+Nephew, INC. | $20.55 | 2025 | Collagenase Santyl |
| Mannkind Corporation | $19.43 | 2021 | |
| Solventum Corporation | $17.27 | 2025 | Promogran Prisma, Activ.A.C. |
| Madrigal Pharmaceuticals | $17.19 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $16.60 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $16.49 | 2025 | |
| Ibsa Pharma INC. | $16.28 | 2023 | Tirosint, Licart |
| Teva Pharmaceuticals USA, INC. | $16.12 | 2019 | |
| Eisai INC. | $15.22 | 2020 | |
| Mylan Specialty L.P. | $13.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.97 | 2019 | |
| Xeris Pharmaceuticals, INC. | $11.92 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Maturo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.